These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26989846)

  • 21. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.
    Poirier L; de Champlain J; Larochelle P; Lamarre-Cliche M; Lacourcière Y
    Blood Press Monit; 2004 Oct; 9(5):231-6. PubMed ID: 15472494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol.
    Salam A; Webster R; Singh K; Kallakuri S; Rodgers A; Prabhakaran D; Maulik PK; Jan S; Thom S; Naik N; Guggilla R; Selak V; Patel A
    Am Heart J; 2014 Feb; 167(2):127-32. PubMed ID: 24439972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.
    Suárez C
    Drugs; 2011 Dec; 71(17):2295-305. PubMed ID: 22085386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
    Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
    Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
    Kinoshita S; Ryuzaki M; Sone M; Nishida E; Nakamoto H;
    Clin Exp Hypertens; 2014; 36(7):508-16. PubMed ID: 24433108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study.
    Ihm SH; Jeon HK; Cha TJ; Hong TJ; Kim SH; Lee NH; Yoon JH; Yoon N; Hwang KK; Jo SH; Youn HJ
    Drug Des Devel Ther; 2016; 10():3817-3826. PubMed ID: 27920497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The Ambulatory Central Aortic Pressure (AmCAP) Study.
    Williams B; Lacy PS; Baschiera F; Brunel P; Düsing R
    Hypertension; 2013 Jun; 61(6):1168-76. PubMed ID: 23630950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
    Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
    Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study.
    Neldam S; Edwards C;
    Am J Geriatr Cardiol; 2006; 15(3):151-60. PubMed ID: 16687967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients.
    Aoki A; Ogawa T; Sumino H; Kumakura H; Takayama Y; Ichikawa S; Nitta K
    Heart Vessels; 2010 May; 25(3):195-202. PubMed ID: 20512446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: the SURGE 2 practice-based study.
    Redon J; Bilo G; Parati G;
    Blood Press; 2013 Dec; 22(6):377-85. PubMed ID: 23957824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial.
    White WB; Weber MA; Davidai G; Neutel JM; Bakris GL; Giles T
    Blood Press Monit; 2005 Jun; 10(3):157-63. PubMed ID: 15923818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination.
    Parati G; Schumacher H
    Hypertens Res; 2014 Mar; 37(3):187-93. PubMed ID: 24305518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.
    Rozza F; Trimarco V; Izzo R; Santoro M; Manzi MV; Marino M; Di Renzo G; Trimarco B
    High Blood Press Cardiovasc Prev; 2013 Mar; 20(1):25-32. PubMed ID: 23657962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.